| Autor: |
Low, May, Boodhoo, Asswade, Moco, Celine, Masento, Sebastian, Tailor, Anish, Ohana, Danielle |
| Předmět: |
|
| Zdroj: |
Journal of Oncology Pharmacy Practice; 2023 Supplement, Vol. 29, p88-89, 2p |
| Abstrakt: |
Background: University College London Hospital (UCLH) launched a pilot Bortezomib self-administration service in multiple myeloma patients. Patients or carer(s) were able to self-administer systemic anti-cancer therapy (SACT) in the comfort of the patient’s home to improve their quality of life. Self-administration of SACT can reduce travel and waiting times for treatment, and impact to personal commitments for example work or childcare whilst receiving treatment. A Macmillan survey estimated an average cost of £170 a month in 70% of patients attending outpatient chemotherapy appointments.1 These can cumulatively impact the quality of life, especially with bi-weekly or weekly regimens containing bortezomib. Furthermore, the introduction of the self-administration service should reduce chemotherapy unit pressures and aseptic workload by utilising outsourced SACT with an extended expiration. Patients were assessed for suitability for self-administration, consented to self-administration and trained during their first cycle of treatment. For subsequent cycles, patients attended daycare for the administration of their first dose and subsequent doses within the cycle were collected by or delivered to the patient. On self-administration treatment days, a trained nurse conducted telephone consultations to assess toxicity and ensure the safe administration of SACT. Objectives: To evaluate the patient experience of all patients who had completed treatment on the pilot bortezomib self-administration service over 12 months. Method: Patients enrolled in the self-administration programme between June 2021 and June 2022 were identified using Trust electronic prescribing system (Epic®). A senior nurse conducted telephone interviews with all patients who had completed treatment in July 2022. Five questions were asked using open and closed questions. Data were collected and analysed on Microsoft Excel with patient-identifiable information anonymised. Thematic analysis was used for qualitative analysis. Results: During the audit period, 10 patients had completed treatment on the self-administration service. All patients were contactable and consented to telephone interviews. Qualitative themes identified from telephone interviews are listed in Table 1. All patients rated the self-administration service as either good or excellent. None of the patients preferred to revert to nurse-administered treatment. Self-administration at home was reported to be more comfortable and easier. Some patients reported saving in travel time and cost. In addition, the training instilled confidence in the patients to self-administer SACT and empowered them in their disease management. Telephone consultations on each self-administration treatment day were reassuring and provided safety at the start of treatment for all patients. Patients also reported that they were comfortable to voice concerns as the nurse would be able to help them should they run into issues. There are a few reported issues with SACT delivery, mainly delays in delivery or unknown delivery times which resulted in anxiety waiting to receive chemotherapy. Conclusion: This evaluation provides a brief insight into our patient experience with the pilot bortezomib self-administration service. Overall patient’s experience of bortezomib self-administration was positive. The delivery service should be audited to identify issues and trends, and to further improve the service if there are delays. A re-evaluation should occur as the service expands to more patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
